{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,8]],"date-time":"2026-02-08T04:21:50Z","timestamp":1770524510832,"version":"3.49.0"},"publisher-location":"Cham","reference-count":119,"publisher":"Springer Nature Switzerland","isbn-type":[{"value":"9783031849879","type":"print"},{"value":"9783031849886","type":"electronic"}],"license":[{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025]]},"DOI":"10.1007\/978-3-031-84988-6_7","type":"book-chapter","created":{"date-parts":[[2025,6,9]],"date-time":"2025-06-09T06:56:24Z","timestamp":1749452184000},"page":"129-148","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Acute Myeloid Leukemia-Use of Measurable Residual Disease to Improve Outcomes"],"prefix":"10.1007","author":[{"given":"Jesse M.","family":"Tettero","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christopher S.","family":"Hourigan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,6,10]]},"reference":[{"issue":"2","key":"7_CR1","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1200\/JCO.2016.67.1875","volume":"35","author":"M Balsat","year":"2017","unstructured":"Balsat M, Renneville A, Thomas X, Botton S, Caillot D, Marceau A et al (2017) Postinduction minimal residual disease predicts outcome and benefit from allogeneic stem cell transplantation in acute myeloid leukemia with NPM1 mutation: a study by the Acute Leukemia French Association Group. J Clin Oncol 35(2):185\u2013193","journal-title":"J Clin Oncol"},{"key":"7_CR2","doi-asserted-by":"publisher","first-page":"3284","DOI":"10.1182\/bloodadvances.2022009391","volume":"7","author":"A Bazinet","year":"2023","unstructured":"Bazinet A, Kadia TM, Short NJ, Borthakur G, Wang SA, Wang W et al (2023) Undetectable measurable residual disease is associated with improved outcomes in AML irrespective of treatment intensity. Blood Adv 7:3284","journal-title":"Blood Adv"},{"issue":"10","key":"7_CR3","doi-asserted-by":"publisher","first-page":"1757","DOI":"10.1007\/s00277-018-3373-y","volume":"97","author":"M Bill","year":"2018","unstructured":"Bill M, Grimm J, Jentzsch M, Kloss L, Goldmann K, Schulz J et al (2018) Digital droplet PCR-based absolute quantification of pre-transplant NPM1 mutation burden predicts relapse in acute myeloid leukemia patients. Ann Hematol 97(10):1757\u20131765","journal-title":"Ann Hematol"},{"issue":"12","key":"7_CR4","doi-asserted-by":"publisher","first-page":"2810","DOI":"10.3324\/haematol.2022.282034","volume":"107","author":"JS Blachly","year":"2022","unstructured":"Blachly JS, Walter RB, Hourigan CS (2022) The present and future of measurable residual disease testing in acute myeloid leukemia. Haematologica 107(12):2810\u20132822","journal-title":"Haematologica"},{"issue":"13","key":"7_CR5","doi-asserted-by":"publisher","first-page":"2295","DOI":"10.1182\/blood-2009-12-258178","volume":"116","author":"F Buccisano","year":"2010","unstructured":"Buccisano F, Maurillo L, Spagnoli A, Del Principe MI, Fraboni D, Panetta P et al (2010) Cytogenetic and molecular diagnostic characterization combined to postconsolidation minimal residual disease assessment by flow cytometry improves risk stratification in adult acute myeloid leukemia. Blood 116(13):2295\u20132303","journal-title":"Blood"},{"key":"7_CR6","doi-asserted-by":"crossref","unstructured":"Caballero-Vel\u00e1zquez T, P\u00e9rez-L\u00f3pez O, Yeguas Bermejo A, Rodr\u00edguez Arbol\u00ed E, Colado Varela E, Sempere Talens A et al (2023) Prognostic value of measurable residual disease in patients with AML undergoing HSCT: a multicenter study. Cancers (Basel) 15(5)","DOI":"10.3390\/cancers15051609"},{"key":"7_CR7","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/j.exphem.2017.01.005","volume":"49","author":"A Candoni","year":"2017","unstructured":"Candoni A, De Marchi F, Zanini F, Zannier ME, Simeone E, Toffoletti E et al (2017a) Predictive value of pretransplantation molecular minimal residual disease assessment by WT1 gene expression in FLT3-positive acute myeloid leukemia. Exp Hematol 49:25\u201333","journal-title":"Exp Hematol"},{"key":"7_CR8","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1016\/j.leukres.2017.10.010","volume":"63","author":"A Candoni","year":"2017","unstructured":"Candoni A, De Marchi F, Zannier ME, Lazzarotto D, Fil\u00ec C, Dubbini MV et al (2017b) High prognostic value of pre-allogeneic stem cell transplantation minimal residual disease detection by WT1 gene expression in AML transplanted in cytologic complete remission. Leuk Res 63:22\u201327","journal-title":"Leuk Res"},{"issue":"11","key":"7_CR9","doi-asserted-by":"publisher","first-page":"1258","DOI":"10.1200\/JCO.2014.58.3518","volume":"33","author":"X Chen","year":"2015","unstructured":"Chen X, Xie H, Wood BL, Walter RB, Pagel JM, Becker PS et al (2015) Relation of clinical response and minimal residual disease and their prognostic impact on outcome in acute myeloid leukemia. J Clin Oncol 33(11):1258\u20131264","journal-title":"J Clin Oncol"},{"issue":"5","key":"7_CR10","doi-asserted-by":"publisher","first-page":"998","DOI":"10.1038\/sj.leu.2404637","volume":"21","author":"WC Chou","year":"2007","unstructured":"Chou WC, Tang JL, Wu SJ, Tsay W, Yao M, Huang SY et al (2007) Clinical implications of minimal residual disease monitoring by quantitative polymerase chain reaction in acute myeloid leukemia patients bearing nucleophosmin (NPM1) mutations. Leukemia 21(5):998\u20131004","journal-title":"Leukemia"},{"issue":"31","key":"7_CR11","doi-asserted-by":"publisher","first-page":"5195","DOI":"10.1200\/JCO.2009.22.4865","volume":"27","author":"D Cilloni","year":"2009","unstructured":"Cilloni D, Renneville A, Hermitte F, Hills RK, Daly S, Jovanovic JV et al (2009) Real-time quantitative polymerase chain reaction detection of minimal residual disease by standardized WT1 assay to enhance risk stratification in acute myeloid leukemia: a European LeukemiaNet study. J Clin Oncol 27(31):5195\u20135201","journal-title":"J Clin Oncol"},{"key":"7_CR12","first-page":"56386","volume":"133","author":"J Cloos","year":"2018","unstructured":"Cloos J, Harris JR, Janssen JJWM, Kelder A, Huang F, Sijm G et al (2018) Comprehensive protocol to sample and process bone marrow for measuring measurable residual disease and leukemic stem cells in acute myeloid leukemia. JoVE 133:56386","journal-title":"JoVE"},{"issue":"5","key":"7_CR13","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1182\/blood.2024024264","volume":"144","author":"JA Cook","year":"2024","unstructured":"Cook JA, Lott L, Perry J, Eckel AM, Xu D, Hudson CA et al (2024) Fusion-harboring mast cells can explain molecular positivity in flow cytometric MRD-negative core-binding factor AML. Blood 144(5):581\u2013585","journal-title":"Blood"},{"issue":"1","key":"7_CR14","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1182\/blood-2015-07-604546","volume":"127","author":"JJ Cornelissen","year":"2016","unstructured":"Cornelissen JJ, Blaise D (2016) Hematopoietic stem cell transplantation for patients with AML in first complete remission. Blood 127(1):62\u201370","journal-title":"Blood"},{"issue":"7","key":"7_CR15","doi-asserted-by":"publisher","first-page":"768","DOI":"10.1200\/JCO.20.02308","volume":"39","author":"C Craddock","year":"2021","unstructured":"Craddock C, Jackson A, Loke J, Siddique S, Hodgkinson A, Mason J et al (2021) Augmented reduced-intensity regimen does not improve postallogeneic transplant outcomes in acute myeloid leukemia. J Clin Oncol 39(7):768\u2013778","journal-title":"J Clin Oncol"},{"issue":"2","key":"7_CR16","doi-asserted-by":"publisher","first-page":"297","DOI":"10.3324\/haematol.2018.203133","volume":"104","author":"LW Dillon","year":"2019","unstructured":"Dillon LW, Hayati S, Roloff GW, Tunc I, Pirooznia M, Mitrofanova A et al (2019) Targeted RNA-sequencing for the quantification of measurable residual disease in acute myeloid leukemia. Haematologica 104(2):297\u2013304","journal-title":"Haematologica"},{"issue":"9","key":"7_CR17","doi-asserted-by":"publisher","first-page":"745","DOI":"10.1001\/jama.2023.1363","volume":"329","author":"LW Dillon","year":"2023","unstructured":"Dillon LW, Gui G, Page KM, Ravindra N, Wong ZC, Andrew G et al (2023) DNA sequencing to detect residual disease in adults with acute myeloid leukemia prior to hematopoietic cell transplant. JAMA 329(9):745\u2013755","journal-title":"JAMA"},{"issue":"12","key":"7_CR18","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.1182\/blood.2022016867","volume":"140","author":"H D\u00f6hner","year":"2022","unstructured":"D\u00f6hner H, Wei AH, Appelbaum FR, Craddock C, DiNardo CD, Dombret H et al (2022) Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN. Blood 140(12):1345\u20131377","journal-title":"Blood"},{"issue":"11","key":"7_CR19","doi-asserted-by":"publisher","first-page":"5063","DOI":"10.1182\/blood-2007-02-072470","volume":"109","author":"A Dominietto","year":"2007","unstructured":"Dominietto A, Pozzi S, Miglino M, Albarracin F, Piaggio G, Bertolotti F et al (2007) Donor lymphocyte infusions for the treatment of minimal residual disease in acute leukemia. Blood 109(11):5063\u20135064","journal-title":"Blood"},{"key":"7_CR20","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1016\/j.leukres.2018.02.006","volume":"67","author":"ZD Epstein-Peterson","year":"2018","unstructured":"Epstein-Peterson ZD, Devlin SM, Stein EM, Estey E, Tallman MS (2018) Widespread use of measurable residual disease in acute myeloid leukemia practice. Leuk Res 67:92\u201398","journal-title":"Leuk Res"},{"issue":"8","key":"7_CR21","doi-asserted-by":"publisher","first-page":"1380","DOI":"10.1038\/sj.leu.2403405","volume":"18","author":"N Feller","year":"2004","unstructured":"Feller N, van der Pol MA, van Stijn A, Weijers GWD, Westra AH, Evertse BW et al (2004) MRD parameters using immunophenotypic detection methods are highly reliable in predicting survival in acute myeloid leukaemia. Leukemia 18(8):1380\u20131390","journal-title":"Leukemia"},{"issue":"8","key":"7_CR22","doi-asserted-by":"publisher","first-page":"e129","DOI":"10.1038\/bcj.2013.27","volume":"3","author":"N Feller","year":"2013","unstructured":"Feller N, van der Velden VHJ, Brooimans RA, Boeckx N, Preijers F, Kelder A et al (2013) Defining consensus leukemia-associated immunophenotypes for detection of minimal residual disease in acute myeloid leukemia in a multicenter setting. Blood Cancer J 3(8):e129\u2013e129","journal-title":"Blood Cancer J"},{"issue":"1","key":"7_CR23","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1182\/hematology.2019000060","volume":"2019","author":"SD Freeman","year":"2019","unstructured":"Freeman SD, Hourigan CS (2019) MRD evaluation of AML in clinical practice: are we there yet? Hematology Am Soc Hematol Educ Program 2019(1):557\u2013569","journal-title":"Hematology Am Soc Hematol Educ Program"},{"issue":"32","key":"7_CR24","doi-asserted-by":"publisher","first-page":"4123","DOI":"10.1200\/JCO.2013.49.1753","volume":"31","author":"SD Freeman","year":"2013","unstructured":"Freeman SD, Virgo P, Couzens S, Grimwade D, Russell N, Hills RK et al (2013) Prognostic relevance of treatment response measured by flow cytometric residual disease detection in older patients with acute myeloid leukemia. J Clin Oncol 31(32):4123\u20134131","journal-title":"J Clin Oncol"},{"issue":"15","key":"7_CR25","doi-asserted-by":"publisher","first-page":"1486","DOI":"10.1200\/JCO.2017.76.3425","volume":"36","author":"SD Freeman","year":"2018","unstructured":"Freeman SD, Hills RK, Virgo P, Khan N, Couzens S, Dillon R et al (2018) Measurable residual disease at induction redefines partial response in acute myeloid leukemia and stratifies outcomes in patients at standard risk without NPM1 mutations. J Clin Oncol 36(15):1486\u20131497","journal-title":"J Clin Oncol"},{"issue":"1","key":"7_CR26","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1111\/bjh.16362","volume":"188","author":"J Ghannam","year":"2020","unstructured":"Ghannam J, Dillon LW, Hourigan CS (2020) Next-generation sequencing for measurable residual disease detection in acute myeloid leukaemia. Br J Haematol 188(1):77\u201385","journal-title":"Br J Haematol"},{"issue":"5","key":"7_CR27","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1038\/s41408-021-00479-3","volume":"11","author":"MH Gilleece","year":"2021","unstructured":"Gilleece MH, Shimoni A, Labopin M, Robinson S, Beelen D, Soci\u00e9 G et al (2021) Measurable residual disease status and outcome of transplant in acute myeloid leukemia in second complete remission: a study by the acute leukemia working party of the EBMT. Blood Cancer J 11(5):88","journal-title":"Blood Cancer J"},{"issue":"6","key":"7_CR28","doi-asserted-by":"publisher","first-page":"1103","DOI":"10.1038\/sj.leu.2404149","volume":"20","author":"P Gorello","year":"2006","unstructured":"Gorello P, Cazzaniga G, Alberti F, Dell'Oro MG, Gottardi E, Specchia G et al (2006) Quantitative assessment of minimal residual disease in acute myeloid leukemia carrying nucleophosmin (NPM1) gene mutations. Leukemia 20(6):1103\u20131108","journal-title":"Leukemia"},{"issue":"23","key":"7_CR29","doi-asserted-by":"publisher","first-page":"3345","DOI":"10.1182\/blood-2014-05-577593","volume":"124","author":"D Grimwade","year":"2014","unstructured":"Grimwade D, Freeman SD (2014) Defining minimal residual disease in acute myeloid leukemia: which platforms are ready for \u201cprime time\u201d? Blood 124(23):3345\u20133355","journal-title":"Blood"},{"issue":"1","key":"7_CR30","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1182\/blood-2015-07-604496","volume":"127","author":"D Grimwade","year":"2016","unstructured":"Grimwade D, Ivey A, Huntly BJ (2016) Molecular landscape of acute myeloid leukemia in younger adults and its clinical relevance. Blood 127(1):29\u201341","journal-title":"Blood"},{"issue":"15","key":"7_CR31","doi-asserted-by":"publisher","first-page":"2347","DOI":"10.1182\/blood.2021014472","volume":"139","author":"T Grob","year":"2022","unstructured":"Grob T, Al Hinai ASA, Sanders MA, Kavelaars FG, Rijken M, Gradowska PL et al (2022) Molecular characterization of mutant TP53 acute myeloid leukemia and high-risk myelodysplastic syndrome. Blood 139(15):2347\u20132354","journal-title":"Blood"},{"issue":"4","key":"7_CR32","doi-asserted-by":"publisher","first-page":"756","DOI":"10.1200\/JCO.22.00715","volume":"41","author":"T Grob","year":"2023","unstructured":"Grob T, Sanders MA, Vonk CM, Kavelaars FG, Rijken M, Hanekamp DW et al (2023) Prognostic value of FLT3-internal tandem duplication residual disease in acute myeloid leukemia. J Clin Oncol 41(4):756\u2013765","journal-title":"J Clin Oncol"},{"issue":"2","key":"7_CR33","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1016\/j.pathol.2019.09.021","volume":"52","author":"D Hanekamp","year":"2020","unstructured":"Hanekamp D, Bachas C, van de Loosdrecht A, Ossenkoppele G, Cloos J (2020) Re: Myeloblasts in normal bone marrows expressing leukaemia-associated immunophenotypes. Pathology 52(2):289\u2013291","journal-title":"Pathology"},{"issue":"26","key":"7_CR34","doi-asserted-by":"publisher","first-page":"2753","DOI":"10.1182\/blood.2021013626","volume":"138","author":"M Heuser","year":"2021","unstructured":"Heuser M, Freeman SD, Ossenkoppele GJ, Buccisano F, Hourigan CS, Ngai LL et al (2021a) 2021 Update on MRD in acute myeloid leukemia: a consensus document from the European LeukemiaNet MRD Working Party. Blood 138(26):2753\u20132767","journal-title":"Blood"},{"issue":"9","key":"7_CR35","doi-asserted-by":"publisher","first-page":"2294","DOI":"10.1182\/bloodadvances.2021004367","volume":"5","author":"M Heuser","year":"2021","unstructured":"Heuser M, Heida B, B\u00fcttner K, Wienecke CP, Teich K, Funke C et al (2021b) Posttransplantation MRD monitoring in patients with AML by next-generation sequencing using DTA and non-DTA mutations. Blood Adv 5(9):2294\u20132304","journal-title":"Blood Adv"},{"issue":"9","key":"7_CR36","doi-asserted-by":"publisher","first-page":"2577","DOI":"10.1182\/blood-2010-09-303685","volume":"117","author":"P Hokland","year":"2011","unstructured":"Hokland P, Ommen HB (2011) Towards individualized follow-up in adult acute myeloid leukemia in remission. Blood 117(9):2577\u20132584","journal-title":"Blood"},{"issue":"8","key":"7_CR37","doi-asserted-by":"publisher","first-page":"460","DOI":"10.1038\/nrclinonc.2013.100","volume":"10","author":"CS Hourigan","year":"2013","unstructured":"Hourigan CS, Karp JE (2013) Minimal residual disease in acute myeloid leukaemia. Nat Rev Clin Oncol 10(8):460\u2013471","journal-title":"Nat Rev Clin Oncol"},{"issue":"12","key":"7_CR38","doi-asserted-by":"publisher","first-page":"1273","DOI":"10.1200\/JCO.19.03011","volume":"38","author":"CS Hourigan","year":"2020","unstructured":"Hourigan CS, Dillon LW, Gui G, Logan BR, Fei M, Ghannam J et al (2020) Impact of conditioning intensity of allogeneic transplantation for acute myeloid leukemia with genomic evidence of residual disease. J Clin Oncol 38(12):1273\u20131283","journal-title":"J Clin Oncol"},{"issue":"8","key":"7_CR39","doi-asserted-by":"publisher","first-page":"1317","DOI":"10.3324\/haematol.2014.104133","volume":"99","author":"M Hubmann","year":"2014","unstructured":"Hubmann M, K\u00f6hnke T, Hoster E, Schneider S, Dufour A, Zellmeier E et al (2014) Molecular response assessment by quantitative real-time polymerase chain reaction after induction therapy in NPM1-mutated patients identifies those at high risk of relapse. Haematologica 99(8):1317\u20131325","journal-title":"Haematologica"},{"issue":"29","key":"7_CR40","doi-asserted-by":"publisher","first-page":"3625","DOI":"10.1200\/JCO.2011.41.5323","volume":"30","author":"H Inaba","year":"2012","unstructured":"Inaba H, Coustan-Smith E, Cao X, Pounds SB, Shurtleff SA, Wang KY et al (2012) Comparative analysis of different approaches to measure treatment response in acute myeloid leukemia. J Clin Oncol 30(29):3625\u20133632","journal-title":"J Clin Oncol"},{"issue":"Supplement 1","key":"7_CR41","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1182\/blood-2022-164849","volume":"140","author":"GC Issa","year":"2022","unstructured":"Issa GC, Aldoss I, DiPersio JF, Cuglievan B, Stone RM, Arellano ML et al (2022) The menin inhibitor SNDX-5613 (revumenib) leads to durable responses in patients (Pts) with KMT2A-rearranged or NPM1 mutant AML: updated results of a phase (Ph) 1 study. Blood 140(Supplement 1):150\u2013152","journal-title":"Blood"},{"issue":"5","key":"7_CR42","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1056\/NEJMoa1507471","volume":"374","author":"A Ivey","year":"2016","unstructured":"Ivey A, Hills RK, Simpson MA, Jovanovic JV, Gilkes A, Grech A et al (2016) Assessment of minimal residual disease in standard-risk AML. N Engl J Med 374(5):422\u2013433","journal-title":"N Engl J Med"},{"issue":"6","key":"7_CR43","doi-asserted-by":"publisher","first-page":"1337","DOI":"10.3109\/10428194.2013.840776","volume":"55","author":"P Jain","year":"2014","unstructured":"Jain P, Kantarjian H, Patel K, Faderl S, Garcia-Manero G, Benjamini O et al (2014) Mutated NPM1 in patients with acute myeloid leukemia in remission and relapse. Leuk Lymphoma 55(6):1337\u20131344","journal-title":"Leuk Lymphoma"},{"issue":"13","key":"7_CR44","doi-asserted-by":"publisher","first-page":"1189","DOI":"10.1056\/NEJMoa1716863","volume":"378","author":"M Jongen-Lavrencic","year":"2018","unstructured":"Jongen-Lavrencic M, Grob T, Hanekamp D, Kavelaars FG, Aa H, Zeilemaker A et al (2018) Molecular minimal residual disease in acute myeloid leukemia. N Engl J Med 378(13):1189\u20131199","journal-title":"N Engl J Med"},{"issue":"12","key":"7_CR45","doi-asserted-by":"publisher","first-page":"2213","DOI":"10.1182\/blood-2012-10-462879","volume":"121","author":"E Jourdan","year":"2013","unstructured":"Jourdan E, Boissel N, Chevret S, Delabesse E, Renneville A, Cornillet P et al (2013) Prospective evaluation of gene mutations and minimal residual disease in patients with core binding factor acute myeloid leukemia. Blood 121(12):2213\u20132223","journal-title":"Blood"},{"issue":"9","key":"7_CR46","doi-asserted-by":"publisher","first-page":"1986","DOI":"10.1038\/leu.2012.122","volume":"26","author":"T Kalina","year":"2012","unstructured":"Kalina T, Flores-Montero J, van der Velden VHJ, Martin-Ayuso M, B\u00f6ttcher S, Ritgen M et al (2012) EuroFlow standardization of flow cytometer instrument settings and immunophenotyping protocols. Leukemia 26(9):1986\u20132010","journal-title":"Leukemia"},{"issue":"7","key":"7_CR47","doi-asserted-by":"publisher","first-page":"e449","DOI":"10.1038\/bcj.2016.46","volume":"6","author":"S Kayser","year":"2016","unstructured":"Kayser S, Benner A, Thiede C, Martens U, Huber J, Stadtherr P et al (2016) Pretransplant NPM1 MRD levels predict outcome after allogeneic hematopoietic stem cell transplantation in patients with acute myeloid leukemia. Blood Cancer J 6(7):e449\u2013e449","journal-title":"Blood Cancer J"},{"issue":"15","key":"7_CR48","doi-asserted-by":"publisher","first-page":"1604","DOI":"10.1182\/blood-2018-04-848028","volume":"132","author":"T Kim","year":"2018","unstructured":"Kim T, Moon JH, Ahn J-S, Kim Y-K, Lee S-S, Ahn S-Y et al (2018) Next-generation sequencing\u2013based posttransplant monitoring of acute myeloid leukemia identifies patients at high risk of relapse. Blood 132(15):1604\u20131613","journal-title":"Blood"},{"issue":"2","key":"7_CR49","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1038\/leu.2014.186","volume":"29","author":"T K\u00f6hnke","year":"2015","unstructured":"K\u00f6hnke T, Sauter D, Ringel K, Hoster E, Laubender RP, Hubmann M et al (2015) Early assessment of minimal residual disease in AML by flow cytometry during aplasia identifies patients at increased risk of relapse. Leukemia 29(2):377\u2013386","journal-title":"Leukemia"},{"issue":"22","key":"7_CR50","doi-asserted-by":"publisher","first-page":"2349","DOI":"10.1001\/jama.2009.813","volume":"301","author":"J Koreth","year":"2009","unstructured":"Koreth J, Schlenk R, Kopecky KJ, Honda S, Sierra J, Djulbegovic BJ et al (2009) Allogeneic stem cell transplantation for acute myeloid leukemia in first complete remission: systematic review and meta-analysis of prospective clinical trials. JAMA 301(22):2349\u20132361","journal-title":"JAMA"},{"issue":"19","key":"7_CR51","doi-asserted-by":"publisher","first-page":"2709","DOI":"10.1200\/JCO.2011.35.0371","volume":"29","author":"J Kr\u00f6nke","year":"2011","unstructured":"Kr\u00f6nke J, Schlenk RF, Jensen KO, Tsch\u00fcrtz F, Corbacioglu A, Gaidzik VI et al (2011) Monitoring of minimal residual disease in NPM1-mutated acute myeloid leukemia: a study from the German-Austrian Acute Myeloid Leukemia Study Group. J Clin Oncol 29(19):2709\u20132716","journal-title":"J Clin Oncol"},{"issue":"8","key":"7_CR52","doi-asserted-by":"publisher","first-page":"1769","DOI":"10.1038\/leu.2016.44","volume":"30","author":"F Lacombe","year":"2016","unstructured":"Lacombe F, Bernal E, Bloxham D, Couzens S, Porta MGD, Johansson U et al (2016) Harmonemia: a universal strategy for flow cytometry immunophenotyping \u2013 a European LeukemiaNet WP10 study. Leukemia 30(8):1769\u20131772","journal-title":"Leukemia"},{"issue":"2","key":"7_CR53","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1002\/hon.2488","volume":"36","author":"F Lacombe","year":"2018","unstructured":"Lacombe F, Campos L, Allou K, Arnoulet C, Delabarthe A, Dumezy F et al (2018) Prognostic value of multicenter flow cytometry harmonized assessment of minimal residual disease in acute myeloblastic leukemia. Hematol Oncol 36(2):422\u2013428","journal-title":"Hematol Oncol"},{"issue":"23","key":"7_CR54","doi-asserted-by":"publisher","first-page":"5258","DOI":"10.1182\/bloodadvances.2021004322","volume":"5","author":"J Lambert","year":"2021","unstructured":"Lambert J, Lambert J, Thomas X, Marceau-Renaut A, Micol JB, Renneville A et al (2021) Early detection of WT1 measurable residual disease identifies high-risk patients, independent of transplantation in AML. Blood Adv 5(23):5258\u20135268","journal-title":"Blood Adv"},{"key":"7_CR55","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1186\/1471-2105-6-62","volume":"6","author":"A Larionov","year":"2005","unstructured":"Larionov A, Krause A, Miller W (2005) A standard curve based method for relative real time PCR data processing. BMC Bioinformatics 6:62","journal-title":"BMC Bioinformatics"},{"issue":"15","key":"7_CR56","doi-asserted-by":"publisher","first-page":"1766","DOI":"10.1200\/JCO.23.02474","volume":"42","author":"MJ Levis","year":"2024","unstructured":"Levis MJ, Hamadani M, Logan B, Jones RJ, Singh AK, Litzow M et al (2024) Gilteritinib as post-transplant maintenance for AML with internal tandem duplication mutation of FLT3. J Clin Oncol 42(15):1766\u20131775","journal-title":"J Clin Oncol"},{"issue":"7","key":"7_CR57","doi-asserted-by":"publisher","first-page":"929","DOI":"10.1016\/j.bbmt.2014.03.008","volume":"20","author":"J Liu","year":"2014","unstructured":"Liu J, Wang Y, Xu L-P, Liu D-H, Qin Y-Z, Chang Y-J et al (2014) Monitoring mixed lineage leukemia expression may help identify patients with mixed lineage leukemia\u2013rearranged acute leukemia who are at high risk of relapse after allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 20(7):929\u2013936","journal-title":"Biol Blood Marrow Transplant"},{"issue":"4","key":"7_CR58","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1038\/s41409-018-0300-8","volume":"54","author":"J Liu","year":"2019","unstructured":"Liu J, Ma R, Liu Y-R, Xu L-P, Zhang X-H, Chen H et al (2019) The significance of peri-transplantation minimal residual disease assessed by multiparameter flow cytometry on outcomes for adult AML patients receiving haploidentical allografts. Bone Marrow Transplant 54(4):567\u2013577","journal-title":"Bone Marrow Transplant"},{"key":"7_CR59","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.677833","volume":"11","author":"FJ Liu","year":"2021","unstructured":"Liu FJ, Cheng WY, Lin XJ, Wang SY, Jiang TY, Ma TT et al (2021) Measurable residual disease detected by multiparameter flow cytometry and sequencing improves prediction of relapse and survival in acute myeloid leukemia. Front Oncol 11:677833","journal-title":"Front Oncol"},{"issue":"6","key":"7_CR60","doi-asserted-by":"publisher","first-page":"1054","DOI":"10.1111\/bjh.17347","volume":"192","author":"S Loghavi","year":"2021","unstructured":"Loghavi S, DiNardo CD, Furudate K, Takahashi K, Tanaka T, Short NJ et al (2021) Flow cytometric immunophenotypic alterations of persistent clonal haematopoiesis in remission bone marrows of patients with NPM1-mutated acute myeloid leukaemia. Br J Haematol 192(6):1054\u20131063","journal-title":"Br J Haematol"},{"issue":"14","key":"7_CR61","doi-asserted-by":"publisher","first-page":"3666","DOI":"10.1182\/bloodadvances.2022009493","volume":"7","author":"J Loke","year":"2023","unstructured":"Loke J, McCarthy N, Jackson A, Siddique S, Hodgkinson A, Mason J et al (2023) Posttransplant MRD and T-cell chimerism status predict outcomes in patients who received allografts for AML\/MDS. Blood Adv 7(14):3666\u20133676","journal-title":"Blood Adv"},{"issue":"22","key":"7_CR62","doi-asserted-by":"publisher","first-page":"2407","DOI":"10.1182\/blood.2022016567","volume":"140","author":"S Loo","year":"2022","unstructured":"Loo S, Dillon R, Ivey A, Anstee NS, Othman J, Tiong IS et al (2022) Pretransplant FLT3-ITD MRD assessed by high-sensitivity PCR-NGS determines posttransplant clinical outcome. Blood 140(22):2407\u20132411","journal-title":"Blood"},{"issue":"4","key":"7_CR63","doi-asserted-by":"publisher","first-page":"1110","DOI":"10.1182\/bloodadvances.2020003855","volume":"5","author":"B L\u00f6wenberg","year":"2021","unstructured":"L\u00f6wenberg B, Pabst T, Maertens J, Gradowska P, Biemond BJ, Spertini O et al (2021) Addition of lenalidomide to intensive treatment in younger and middle-aged adults with newly diagnosed AML: the HOVON-SAKK-132 trial. Blood Adv 5(4):1110\u20131121","journal-title":"Blood Adv"},{"issue":"8","key":"7_CR64","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1200\/JOP.2017.021675","volume":"13","author":"MR Luskin","year":"2017","unstructured":"Luskin MR, Stone RM (2017) Can minimal residual disease determination in acute myeloid leukemia be used in clinical practice? J Oncol Pract 13(8):471\u2013480","journal-title":"J Oncol Pract"},{"issue":"3","key":"7_CR65","doi-asserted-by":"publisher","first-page":"364","DOI":"10.1038\/sj.leu.2401678","volume":"14","author":"M Mancini","year":"2000","unstructured":"Mancini M, Cedrone M, Diverio D, Emanuel B, Stul M, Vranckx H et al (2000) Use of dual-color interphase FISH for the detection of inv(16) in acute myeloid leukemia at diagnosis, relapse and during follow-up: a study of 23 patients. Leukemia 14(3):364\u2013368","journal-title":"Leukemia"},{"issue":"5","key":"7_CR66","doi-asserted-by":"publisher","first-page":"605","DOI":"10.3324\/haematol.10432","volume":"92","author":"L Maurillo","year":"2007","unstructured":"Maurillo L, Buccisano F, Spagnoli A, Del Poeta G, Panetta P, Neri B et al (2007) Monitoring of minimal residual disease in adult acute myeloid leukemia using peripheral blood as an alternative source to bone marrow. Haematologica 92(5):605\u2013611","journal-title":"Haematologica"},{"issue":"18","key":"7_CR67","doi-asserted-by":"publisher","first-page":"1788","DOI":"10.1200\/JCO.2017.77.6757","volume":"36","author":"K Morita","year":"2018","unstructured":"Morita K, Kantarjian HM, Wang F, Yan Y, Bueso-Ramos C, Sasaki K et al (2018) Clearance of Somatic Mutations at Remission and the Risk of Relapse in Acute Myeloid Leukemia. J Clin Oncol 36(18):1788\u20131797","journal-title":"J Clin Oncol"},{"issue":"6","key":"7_CR68","doi-asserted-by":"publisher","first-page":"1169","DOI":"10.1111\/bjh.18765","volume":"201","author":"A Nagler","year":"2023","unstructured":"Nagler A, Labopin M, Dholaria B, Blaise D, Bondarenko S, Vydra J et al (2023) Impact of measurable residual disease on outcomes of unrelated donor haematopoietic cell transplantation with post-transplant cyclophosphamide in AML in first complete remission. Br J Haematol 201(6):1169\u20131178","journal-title":"Br J Haematol"},{"issue":"11","key":"7_CR69","doi-asserted-by":"publisher","first-page":"2157","DOI":"10.1038\/leu.2013.111","volume":"27","author":"JF Nomded\u00e9u","year":"2013","unstructured":"Nomded\u00e9u JF, Hoyos M, Carricondo M, Bussaglia E, Estivill C, Esteve J et al (2013) Bone marrow WT1 levels at diagnosis, post-induction and post-intensification in adult de novo AML. Leukemia 27(11):2157\u20132164","journal-title":"Leukemia"},{"issue":"5","key":"7_CR70","doi-asserted-by":"publisher","first-page":"436","DOI":"10.1111\/ejh.12511","volume":"95","author":"HB Ommen","year":"2015","unstructured":"Ommen HB, Touzart A, MacIntyre E, Kern W, Haferlach T, Haferlach C et al (2015) The kinetics of relapse in \u2212214-positive acute myeloid leukemia patients. Eur J Haematol 95(5):436\u2013441","journal-title":"Eur J Haematol"},{"issue":"21","key":"7_CR71","doi-asserted-by":"publisher","first-page":"5580","DOI":"10.1182\/bloodadvances.2020002544","volume":"4","author":"B Oran","year":"2020","unstructured":"Oran B, de Lima M, Garcia-Manero G, Thall PF, Lin R, Popat U et al (2020) A phase 3 randomized study of 5-azacitidine maintenance vs observation after transplant in high-risk AML and MDS patients. Blood Adv 4(21):5580\u20135588","journal-title":"Blood Adv"},{"issue":"1","key":"7_CR72","doi-asserted-by":"publisher","first-page":"356","DOI":"10.1182\/asheducation-2016.1.356","volume":"2016","author":"G Ossenkoppele","year":"2016","unstructured":"Ossenkoppele G, Schuurhuis GJ (2016) MRD in AML: does it already guide therapy decision-making? Hematology Am Soc Hematol Educ Program 2016(1):356\u2013365","journal-title":"Hematology Am Soc Hematol Educ Program"},{"issue":"2","key":"7_CR73","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1016\/j.beha.2019.05.003","volume":"32","author":"G Ossenkoppele","year":"2019","unstructured":"Ossenkoppele G, Schuurhuis GJ, van de Loosdrecht A, Cloos J (2019) Can we incorporate MRD assessment into clinical practice in AML? Best Pract Res Clin Haematol 32(2):186\u2013191","journal-title":"Best Pract Res Clin Haematol"},{"issue":"19","key":"7_CR74","doi-asserted-by":"publisher","first-page":"1931","DOI":"10.1182\/blood.2023023096","volume":"143","author":"J Othman","year":"2024","unstructured":"Othman J, Potter N, Ivey A, Jovanovic J, Runglall M, Freeman SD et al (2024) Postinduction molecular MRD identifies patients with NPM1 AML who benefit from allogeneic transplant in first remission. Blood 143(19):1931\u20131936","journal-title":"Blood"},{"issue":"10","key":"7_CR75","doi-asserted-by":"publisher","first-page":"2080","DOI":"10.1038\/leu.2016.120","volume":"30","author":"M Othus","year":"2016","unstructured":"Othus M, Wood BL, Stirewalt DL, Estey EH, Petersdorf SH, Appelbaum FR et al (2016) Effect of measurable (\u2018minimal\u2019) residual disease (MRD) information on prediction of relapse and survival in adult acute myeloid leukemia. Leukemia 30(10):2080\u20132083","journal-title":"Leukemia"},{"key":"7_CR76","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1038\/s41409-019-0729-4","volume":"55","author":"M Othus","year":"2019","unstructured":"Othus M, Gale RP, Hourigan CS, Walter RB (2019) Statistics and measurable residual disease (MRD) testing: uses and abuses in hematopoietic cell transplantation. Bone Marrow Transplant 55:843","journal-title":"Bone Marrow Transplant"},{"issue":"23","key":"7_CR77","doi-asserted-by":"publisher","first-page":"2209","DOI":"10.1056\/NEJMoa1516192","volume":"374","author":"E Papaemmanuil","year":"2016","unstructured":"Papaemmanuil E, Gerstung M, Bullinger L, Gaidzik VI, Paschka P, Roberts ND et al (2016) Genomic classification and prognosis in acute myeloid leukemia. N Engl J Med 374(23):2209\u20132221","journal-title":"N Engl J Med"},{"issue":"11","key":"7_CR78","doi-asserted-by":"publisher","first-page":"1694","DOI":"10.1182\/blood.2021014804","volume":"139","author":"G Paras","year":"2022","unstructured":"Paras G, Morsink LM, Othus M, Milano F, Sandmaier BM, Zarling LC et al (2022) Conditioning intensity and peritransplant flow cytometric MRD dynamics in adult AML. Blood 139(11):1694\u20131706","journal-title":"Blood"},{"issue":"5","key":"7_CR79","doi-asserted-by":"publisher","first-page":"1392","DOI":"10.1038\/s41375-021-01131-6","volume":"35","author":"N Patkar","year":"2021","unstructured":"Patkar N, Kakirde C, Shaikh AF, Salve R, Bhanshe P, Chatterjee G et al (2021) Clinical impact of panel-based error-corrected next generation sequencing versus flow cytometry to detect measurable residual disease (MRD) in acute myeloid leukemia (AML). Leukemia 35(5):1392\u20131404","journal-title":"Leukemia"},{"issue":"4","key":"7_CR80","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1016\/j.blre.2017.01.003","volume":"31","author":"ME Percival","year":"2017","unstructured":"Percival ME, Lai C, Estey E, Hourigan CS (2017) Bone marrow evaluation for diagnosis and monitoring of acute myeloid leukemia. Blood Rev 31(4):185\u2013192","journal-title":"Blood Rev"},{"issue":"12","key":"7_CR81","doi-asserted-by":"publisher","first-page":"1668","DOI":"10.1016\/S1470-2045(18)30580-1","volume":"19","author":"U Platzbecker","year":"2018","unstructured":"Platzbecker U, Middeke JM, Sockel K, Herbst R, Wolf D, Baldus CD et al (2018) Measurable residual disease-guided treatment with azacitidine to prevent haematological relapse in patients with myelodysplastic syndrome and acute myeloid leukaemia (RELAZA2): an open-label, multicentre, phase 2 trial. Lancet Oncol 19(12):1668\u20131679","journal-title":"Lancet Oncol"},{"issue":"2","key":"7_CR82","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1038\/s41375-023-02118-1","volume":"38","author":"S Potluri","year":"2024","unstructured":"Potluri S, Kellaway SG, Coleman DJL, Keane P, Imperato MR, Assi SA et al (2024) Gene regulation in t(6;9) DEK::NUP214 Acute Myeloid Leukemia resembles that of FLT3-ITD\/NPM1 Acute Myeloid Leukemia but with an altered HOX\/MEIS axis. Leukemia 38(2):403\u2013407","journal-title":"Leukemia"},{"issue":"1","key":"7_CR83","doi-asserted-by":"publisher","first-page":"56","DOI":"10.3324\/haematol.2019.235721","volume":"106","author":"R Puckrin","year":"2021","unstructured":"Puckrin R, Atenafu EG, Claudio JO, Chan S, Gupta V, Maze D et al (2021) Measurable residual disease monitoring provides insufficient lead-time to prevent morphologic relapse in the majority of patients with core-binding factor acute myeloid leukemia. Haematologica 106(1):56\u201363","journal-title":"Haematologica"},{"issue":"4","key":"7_CR84","doi-asserted-by":"publisher","first-page":"396","DOI":"10.1016\/j.beha.2018.09.013","volume":"31","author":"F Ravandi","year":"2018","unstructured":"Ravandi F (2018) Is it time to routinely incorporate MRD into practice? Best Pract Res Clin Haematol 31(4):396\u2013400","journal-title":"Best Pract Res Clin Haematol"},{"issue":"3","key":"7_CR85","doi-asserted-by":"publisher","first-page":"426","DOI":"10.1002\/cncr.30361","volume":"123","author":"F Ravandi","year":"2017","unstructured":"Ravandi F, Jorgensen J, Borthakur G, Jabbour E, Kadia T, Pierce S et al (2017) Persistence of minimal residual disease assessed by multiparameter flow cytometry is highly prognostic in younger patients with acute myeloid leukemia. Cancer 123(3):426\u2013435","journal-title":"Cancer"},{"issue":"19","key":"7_CR86","doi-asserted-by":"publisher","first-page":"1608","DOI":"10.1182\/blood.2019001425","volume":"134","author":"FG R\u00fccker","year":"2019","unstructured":"R\u00fccker FG, Agrawal M, Corbacioglu A, Weber D, Kapp-Schwoerer S, Gaidzik VI et al (2019) Measurable residual disease monitoring in acute myeloid leukemia with t(8;21)(q22;q22.1): results from the AML Study Group. Blood 134(19):1608\u20131618","journal-title":"Blood"},{"issue":"11","key":"7_CR87","doi-asserted-by":"publisher","first-page":"2220","DOI":"10.1182\/blood-2009-03-213389","volume":"114","author":"S Schnittger","year":"2009","unstructured":"Schnittger S, Kern W, Tschulik C, Weiss T, Dicker F, Falini B et al (2009) Minimal residual disease levels assessed by NPM1 mutation-specific RQ-PCR provide important prognostic information in AML. Blood 114(11):2220\u20132231","journal-title":"Blood"},{"issue":"12","key":"7_CR88","first-page":"1626","volume":"90","author":"C Scholl","year":"2005","unstructured":"Scholl C, Schlenk RF, Eiwen K, D\u00f6hner H, Fr\u00f6hling S, D\u00f6hner K (2005) The prognostic value of MLL-AF9 detection in patients with t(9;11)(p22;q23)-positive acute myeloid leukemia. Haematologica 90(12):1626\u20131634","journal-title":"Haematologica"},{"issue":"12","key":"7_CR89","doi-asserted-by":"publisher","first-page":"1275","DOI":"10.1182\/blood-2017-09-801498","volume":"131","author":"GJ Schuurhuis","year":"2018","unstructured":"Schuurhuis GJ, Heuser M, Freeman S, B\u00e9n\u00e9 M-C, Buccisano F, Cloos J et al (2018) Minimal\/measurable residual disease in AML: a consensus document from the European LeukemiaNet MRD Working Party. Blood 131(12):1275\u20131291","journal-title":"Blood"},{"issue":"14","key":"7_CR90","doi-asserted-by":"publisher","first-page":"3686","DOI":"10.1182\/bloodadvances.2022009379","volume":"7","author":"S Scott","year":"2023","unstructured":"Scott S, Dillon R, Thiede C, Sadiq S, Cartwright A, Clouston HJ et al (2023) Assessment of acute myeloid leukemia molecular measurable residual disease testing in an interlaboratory study. Blood Adv 7(14):3686\u20133694","journal-title":"Blood Adv"},{"issue":"7","key":"7_CR91","doi-asserted-by":"publisher","first-page":"1638","DOI":"10.1038\/s41375-024-02275-x","volume":"38","author":"S Scott","year":"2024","unstructured":"Scott S, Devonshire A, Dillon R, Thiede C, Cross NCP, White HE et al (2024) Recommendations from the AML molecular MRD expert advisory board. Leukemia 38(7):1638\u20131641","journal-title":"Leukemia"},{"issue":"7","key":"7_CR92","doi-asserted-by":"publisher","first-page":"1514","DOI":"10.1016\/j.bbmt.2018.02.003","volume":"24","author":"MV Shah","year":"2018","unstructured":"Shah MV, Jorgensen JL, Saliba RM, Wang SA, Alousi AM, Andersson BS et al (2018) Early post-transplant minimal residual disease assessment improves risk stratification in acute myeloid leukemia. Biol Blood Marrow Transplant 24(7):1514\u20131520","journal-title":"Biol Blood Marrow Transplant"},{"issue":"1","key":"7_CR93","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1182\/blood-2012-10-461749","volume":"122","author":"N Shayegi","year":"2013","unstructured":"Shayegi N, Kramer M, Bornh\u00e4user M, Schaich M, Schetelig J, Platzbecker U et al (2013) The level of residual disease based on mutant NPM1 is an independent prognostic factor for relapse and survival in AML. Blood 122(1):83\u201392","journal-title":"Blood"},{"issue":"12","key":"7_CR94","doi-asserted-by":"publisher","first-page":"1890","DOI":"10.1001\/jamaoncol.2020.4600","volume":"6","author":"NJ Short","year":"2020","unstructured":"Short NJ, Zhou S, Fu C, Berry DA, Walter RB, Freeman SD et al (2020) Association of measurable residual disease with survival outcomes in patients with acute myeloid leukemia: a systematic review and meta-analysis. JAMA Oncol 6(12):1890\u20131899","journal-title":"JAMA Oncol"},{"issue":"7","key":"7_CR95","doi-asserted-by":"publisher","first-page":"1295","DOI":"10.1038\/sj.leu.2404233","volume":"20","author":"ML Slovak","year":"2006","unstructured":"Slovak ML, Gundacker H, Bloomfield CD, Dewald G, Appelbaum FR, Larson RA et al (2006) A retrospective study of 69 patients with t(6;9)(p23;q34) AML emphasizes the need for a prospective, multicenter initiative for rare \u2018poor prognosis\u2019 myeloid malignancies. Leukemia 20(7):1295\u20131297","journal-title":"Leukemia"},{"issue":"5","key":"7_CR96","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1182\/blood.2020008812","volume":"138","author":"ML Sorror","year":"2021","unstructured":"Sorror ML, Storer BE, Fathi AT, Brunner A, Gerds AT, Sekeres MA et al (2021) Multisite 11-year experience of less-intensive vs intensive therapies in acute myeloid leukemia. Blood 138(5):387\u2013400","journal-title":"Blood"},{"issue":"6","key":"7_CR97","doi-asserted-by":"publisher","first-page":"1493","DOI":"10.1111\/trf.12524","volume":"54","author":"Y Tan","year":"2014","unstructured":"Tan Y, Du K, Luo Y, Shi J, Cao L, Zheng Y et al (2014) Superiority of preemptive donor lymphocyte infusion based on minimal residual disease in acute leukemia patients after allogeneic hematopoietic stem cell transplantation. Transfusion 54(6):1493\u20131500","journal-title":"Transfusion"},{"issue":"31","key":"7_CR98","doi-asserted-by":"publisher","first-page":"3889","DOI":"10.1200\/JCO.2012.45.9628","volume":"31","author":"M Terwijn","year":"2013","unstructured":"Terwijn M, van Putten WL, Kelder A, van der Velden VH, Brooimans RA, Pabst T et al (2013) High prognostic impact of flow cytometric minimal residual disease detection in acute myeloid leukemia: data from the HOVON\/SAKK AML 42A study. J Clin Oncol 31(31):3889\u20133897","journal-title":"J Clin Oncol"},{"issue":"1","key":"7_CR99","volume":"6","author":"JM Tettero","year":"2022","unstructured":"Tettero JM, Freeman S, Buecklein V, Venditti A, Maurillo L, Kern W et al (2022a) Technical aspects of flow cytometry-based measurable residual disease quantification in acute myeloid leukemia: experience of the European LeukemiaNet MRD Working Party. Hema 6(1):e676","journal-title":"Hema"},{"key":"7_CR100","doi-asserted-by":"crossref","unstructured":"Tettero JM, Al-Badri WKW, Ngai LL, Bachas C, Breems DA, van Elssen CHMJ et al (2022b) Concordance in measurable residual disease result after first and second induction cycle in acute myeloid leukemia: an outcome- and cost-analysis. Front Oncol 12","DOI":"10.3389\/fonc.2022.999822"},{"issue":"6","key":"7_CR101","doi-asserted-by":"publisher","first-page":"426","DOI":"10.1002\/cyto.b.22144","volume":"104","author":"JM Tettero","year":"2023","unstructured":"Tettero JM, Dakappagari N, Heidinga ME, Oussoren-Brockhoff Y, Hanekamp D, Pahuja A et al (2023a) Analytical assay validation for acute myeloid leukemia measurable residual disease assessment by multiparametric flow cytometry. Cytometry B Clin Cytom 104(6):426\u2013439","journal-title":"Cytometry B Clin Cytom"},{"issue":"10","key":"7_CR102","doi-asserted-by":"publisher","first-page":"2794","DOI":"10.3324\/haematol.2022.282639","volume":"108","author":"JM Tettero","year":"2023","unstructured":"Tettero JM, Ngai LL, Bachas C, Breems DA, Fischer T, Gjertsen BT et al (2023b) Measurable residual disease-guided therapy in intermediate-risk acute myeloid leukemia patients is a valuable strategy in reducing allogeneic transplantation without negatively affecting survival. Haematologica 108(10):2794\u20132798","journal-title":"Haematologica"},{"issue":"3","key":"7_CR103","doi-asserted-by":"publisher","first-page":"630","DOI":"10.1038\/s41375-024-02158-1","volume":"38","author":"JM Tettero","year":"2024","unstructured":"Tettero JM, Heidinga ME, Mocking TR, Fransen G, Kelder A, Scholten WJ et al (2024) Impact of hemodilution on flow cytometry based measurable residual disease assessment in acute myeloid leukemia. Leukemia 38(3):630\u2013639","journal-title":"Leukemia"},{"issue":"23","key":"7_CR104","doi-asserted-by":"publisher","first-page":"5107","DOI":"10.1182\/bloodadvances.2021005455","volume":"5","author":"IS Tiong","year":"2021","unstructured":"Tiong IS, Dillon R, Ivey A, Kuzich JA, Thiagarajah N, Sharplin KM et al (2021) Clinical impact of NPM1-mutant molecular persistence after chemotherapy for acute myeloid leukemia. Blood Adv 5(23):5107\u20135111","journal-title":"Blood Adv"},{"issue":"10","key":"7_CR105","doi-asserted-by":"publisher","first-page":"2456","DOI":"10.1182\/bloodadvances.2020003738","volume":"5","author":"CH Tsai","year":"2021","unstructured":"Tsai CH, Tang JL, Tien FM, Kuo YY, Wu DC, Lin CC et al (2021) Clinical implications of sequential MRD monitoring by NGS at 2 time points after chemotherapy in patients with AML. Blood Adv 5(10):2456\u20132466","journal-title":"Blood Adv"},{"issue":"11","key":"7_CR106","doi-asserted-by":"publisher","first-page":"2599","DOI":"10.1038\/s41375-019-0477-x","volume":"33","author":"C Ustun","year":"2019","unstructured":"Ustun C, Le-Rademacher J, Wang H-L, Othus M, Sun Z, Major B et al (2019) Allogeneic hematopoietic cell transplantation compared to chemotherapy consolidation in older acute myeloid leukemia (AML) patients 60\u201375 years in first complete remission (CR1): an alliance (A151509), SWOG, ECOG-ACRIN, and CIBMTR study. Leukemia 33(11):2599\u20132609","journal-title":"Leukemia"},{"key":"7_CR1100","unstructured":"Venditti (2025) Blood Adv:https:\/\/ashpublications.org\/bloodadvances\/article\/doi\/10.1182\/bloodadvances.2024013744\/535487\/FITNESS-ASSESSMENTIN-ACUTE-MYELOID-LEUKEMIA"},{"issue":"12","key":"7_CR107","doi-asserted-by":"publisher","first-page":"935","DOI":"10.1182\/blood.2018886960","volume":"134","author":"A Venditti","year":"2019","unstructured":"Venditti A, Piciocchi A, Candoni A, Melillo L, Calafiore V, Cairoli R et al (2019) GIMEMA AML1310 trial of risk-adapted, MRD-directed therapy for young adults with newly diagnosed acute myeloid leukemia. Blood 134(12):935\u2013945","journal-title":"Blood"},{"key":"7_CR108","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.leukres.2015.10.002","volume":"40","author":"MB Vidriales","year":"2016","unstructured":"Vidriales MB, P\u00e9rez-L\u00f3pez E, Pegenaute C, Castellanos M, P\u00e9rez JJ, Chand\u00eda M et al (2016) Minimal residual disease evaluation by flow cytometry is a complementary tool to cytogenetics for treatment decisions in acute myeloid leukaemia. Leuk Res 40:1\u20139","journal-title":"Leuk Res"},{"issue":"1","key":"7_CR109","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1038\/leu.2014.173","volume":"29","author":"RB Walter","year":"2015","unstructured":"Walter RB, Gyurkocza B, Storer BE, Godwin CD, Pagel JM, Buckley SA et al (2015 Jan) Comparison of minimal residual disease as outcome predictor for AML patients in first complete remission undergoing myeloablative or nonmyeloablative allogeneic hematopoietic cell transplantation. Leukemia 29(1):137\u2013144","journal-title":"Leukemia"},{"issue":"3","key":"7_CR110","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1182\/blood.2023022697","volume":"144","author":"CP Wienecke","year":"2024","unstructured":"Wienecke CP, Heida B, Venturini L, Gabdoulline R, Kr\u00fcger K, Teich K et al (2024) Clonal relapse dynamics in acute myeloid leukemia following allogeneic hematopoietic cell transplantation. Blood 144(3):296\u2013307","journal-title":"Blood"},{"issue":"1","key":"7_CR111","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1002\/cyto.b.21239","volume":"90","author":"BL Wood","year":"2016","unstructured":"Wood BL (2016) Principles of minimal residual disease detection for hematopoietic neoplasms by flow cytometry. Cytometry B Clin Cytom 90(1):47\u201353","journal-title":"Cytometry B Clin Cytom"},{"issue":"S1","key":"7_CR112","doi-asserted-by":"publisher","first-page":"S14","DOI":"10.1002\/cyto.b.20363","volume":"72B","author":"BL Wood","year":"2007","unstructured":"Wood BL, Arroz M, Barnett D, DiGiuseppe J, Greig B, Kussick SJ et al (2007) 2006 Bethesda International Consensus recommendations on the immunophenotypic analysis of hematolymphoid neoplasia by flow cytometry: Optimal reagents and reporting for the flow cytometric diagnosis of hematopoietic neoplasia. Cytometry B Clin Cytom 72B(S1):S14\u2013S22","journal-title":"Cytometry B Clin Cytom"},{"issue":"8","key":"7_CR113","doi-asserted-by":"publisher","first-page":"e600","DOI":"10.1016\/S2352-3026(23)00117-5","volume":"10","author":"L Xuan","year":"2023","unstructured":"Xuan L, Wang Y, Yang K, Shao R, Huang F, Fan Z et al (2023) Sorafenib maintenance after allogeneic haemopoietic stem-cell transplantation in patients with FLT3-ITD acute myeloid leukaemia: long-term follow-up of an open-label, multicentre, randomised, phase 3 trial. Lancet Haematol 10(8):e600\u2013e611","journal-title":"Lancet Haematol"},{"issue":"1","key":"7_CR114","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1007\/s12185-019-02759-y","volume":"111","author":"M Yanada","year":"2020","unstructured":"Yanada M, Takami A, Mizuno S, Mori J, Chou T, Usuki K et al (2020) Autologous hematopoietic cell transplantation for acute myeloid leukemia in adults: 25 years of experience in Japan. Int J Hematol 111(1):93\u2013102","journal-title":"Int J Hematol"},{"issue":"14","key":"7_CR115","doi-asserted-by":"publisher","first-page":"2826","DOI":"10.1182\/blood-2012-06-435669","volume":"120","author":"JAL Yin","year":"2012","unstructured":"Yin JAL, O\u2019Brien MA, Hills RK, Daly SB, Wheatley K, Burnett AK (2012) Minimal residual disease monitoring by quantitative RT-PCR in core binding factor AML allows risk stratification and predicts relapse: results of the United Kingdom MRC AML-15 trial. Blood 120(14):2826\u20132835","journal-title":"Blood"},{"issue":"1","key":"7_CR116","doi-asserted-by":"publisher","first-page":"e66","DOI":"10.1002\/cpcy.66","volume":"91","author":"W Zeijlemaker","year":"2019","unstructured":"Zeijlemaker W, Kelder A, Cloos J, Schuurhuis GJ (2019) Immunophenotypic detection of measurable residual (stem cell) disease using LAIP approach in acute myeloid leukemia. Curr Protoc Cytom 91(1):e66\u2013e66","journal-title":"Curr Protoc Cytom"},{"issue":"7","key":"7_CR117","doi-asserted-by":"publisher","first-page":"1456","DOI":"10.1038\/leu.2016.46","volume":"30","author":"Y Zhou","year":"2016","unstructured":"Zhou Y, Othus M, Araki D, Wood BL, Radich JP, Halpern AB et al (2016) Pre- and post-transplant quantification of measurable (\u2018minimal\u2019) residual disease via multiparameter flow cytometry in adult acute myeloid leukemia. Leukemia 30(7):1456\u20131464","journal-title":"Leukemia"},{"issue":"20","key":"7_CR118","doi-asserted-by":"publisher","first-page":"4056","DOI":"10.1182\/blood-2012-11-468348","volume":"121","author":"HH Zhu","year":"2013","unstructured":"Zhu HH, Zhang XH, Qin YZ, Liu DH, Jiang H, Chen H et al (2013) MRD-directed risk stratification treatment may improve outcomes of t(8;21) AML in the first complete remission: results from the AML05 multicenter trial. Blood 121(20):4056\u20134062","journal-title":"Blood"}],"container-title":["Advances in Experimental Medicine and Biology","Clinical Management of Challenges in Allogeneic Stem Cell Transplant"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/978-3-031-84988-6_7","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,9]],"date-time":"2025-06-09T16:04:29Z","timestamp":1749485069000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/978-3-031-84988-6_7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025]]},"ISBN":["9783031849879","9783031849886"],"references-count":119,"URL":"https:\/\/doi.org\/10.1007\/978-3-031-84988-6_7","relation":{},"ISSN":["0065-2598","2214-8019"],"issn-type":[{"value":"0065-2598","type":"print"},{"value":"2214-8019","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025]]},"assertion":[{"value":"10 June 2025","order":1,"name":"first_online","label":"First Online","group":{"name":"ChapterHistory","label":"Chapter History"}}]}}